# A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects

> **NCT01332552** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 27 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** GSK2485852 70 mg
- **DRUG:** GSK2485852 420 mg
- **DRUG:** placebo
- **DRUG:** placebo
- **DRUG:** GSK2485852 420 mg
- **DRUG:** GSK2485852 420 mg
- **DRUG:** GSK2485852 630 mg
- **DRUG:** GSK2485852 70 mg + Ritonavir 100mg
- **DRUG:** GSK2485852 210 mg + Ritonavir 100mg
- **DRUG:** GSK2485852 210 mg +Ritonavir 100mg

## Key facts

- **NCT ID:** NCT01332552
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01-14
- **Primary completion:** 2011-04-06
- **Final completion:** 2011-04-06
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Terminated due to unfavorable human pharmacokinetic properties
- **Last updated:** 2017-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01332552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01332552, "A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01332552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*